Iterum Therapeutics (ITRM) Competitors $0.67 -0.01 (-1.35%) Closing price 04:00 PM EasternExtended Trading$0.68 +0.01 (+1.18%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ITRM vs. ONCY, HURA, TARA, CGEN, IKT, CRBP, BMEA, PYXS, EQ, and FATEShould you be buying Iterum Therapeutics stock or one of its competitors? The main competitors of Iterum Therapeutics include Oncolytics Biotech (ONCY), TuHURA Biosciences (HURA), Protara Therapeutics (TARA), Compugen (CGEN), Inhibikase Therapeutics (IKT), Corbus Pharmaceuticals (CRBP), Biomea Fusion (BMEA), Pyxis Oncology (PYXS), Equillium (EQ), and Fate Therapeutics (FATE). These companies are all part of the "pharmaceutical products" industry. Iterum Therapeutics vs. Its Competitors Oncolytics Biotech TuHURA Biosciences Protara Therapeutics Compugen Inhibikase Therapeutics Corbus Pharmaceuticals Biomea Fusion Pyxis Oncology Equillium Fate Therapeutics Iterum Therapeutics (NASDAQ:ITRM) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation. Which has higher valuation & earnings, ITRM or ONCY? Oncolytics Biotech is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIterum TherapeuticsN/AN/A-$24.77M-$0.85-0.79Oncolytics BiotechN/AN/A-$23.14M-$0.27-5.00 Does the media favor ITRM or ONCY? In the previous week, Oncolytics Biotech had 2 more articles in the media than Iterum Therapeutics. MarketBeat recorded 3 mentions for Oncolytics Biotech and 1 mentions for Iterum Therapeutics. Iterum Therapeutics' average media sentiment score of 1.45 beat Oncolytics Biotech's score of 0.47 indicating that Iterum Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Iterum Therapeutics Positive Oncolytics Biotech Neutral Is ITRM or ONCY more profitable? Iterum Therapeutics' return on equity of 0.00% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Iterum TherapeuticsN/A N/A -65.01% Oncolytics Biotech N/A -438.11%-143.90% Do institutionals and insiders have more ownership in ITRM or ONCY? 9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 2.4% of Iterum Therapeutics shares are owned by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, ITRM or ONCY? Iterum Therapeutics has a beta of 3.04, suggesting that its stock price is 204% more volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Do analysts prefer ITRM or ONCY? Iterum Therapeutics presently has a consensus target price of $9.00, suggesting a potential upside of 1,243.08%. Oncolytics Biotech has a consensus target price of $5.00, suggesting a potential upside of 270.37%. Given Iterum Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Iterum Therapeutics is more favorable than Oncolytics Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Oncolytics Biotech 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 SummaryIterum Therapeutics beats Oncolytics Biotech on 9 of the 13 factors compared between the two stocks. Get Iterum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ITRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITRM vs. The Competition Export to ExcelMetricIterum TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.04M$2.55B$5.75B$10.31BDividend YieldN/A59.99%5.89%4.63%P/E Ratio-0.7923.2976.6626.52Price / SalesN/A481.61445.6888.95Price / CashN/A169.8537.2260.63Price / Book-4.475.2913.946.31Net Income-$24.77M$32.95M$3.29B$271.37M7 Day Performance-3.49%0.85%0.63%2.11%1 Month Performance-22.36%3.80%4.32%6.67%1 Year Performance-39.08%-3.99%84.13%27.84% Iterum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITRMIterum Therapeutics2.9962 of 5 stars$0.67-1.4%$9.00+1,243.1%-35.9%$32.04MN/A-0.7910Positive NewsShort Interest ↓ONCYOncolytics Biotech2.3228 of 5 stars$1.24-3.1%$5.00+303.2%+33.8%$128.46MN/A-4.5930News CoverageGap UpHURATuHURA Biosciences1.4715 of 5 stars$2.39-4.4%$12.67+430.0%N/A$125.12MN/A0.00N/ATARAProtara Therapeutics1.3042 of 5 stars$3.16+0.6%$19.60+520.3%+64.2%$121.15MN/A-1.9530Positive NewsCGENCompugen1.6643 of 5 stars$1.38+3.0%$4.00+189.9%-28.1%$119.58M$27.86M-6.2770Positive NewsIKTInhibikase Therapeutics1.3151 of 5 stars$1.60+2.6%$6.50+306.3%+34.5%$119.23MN/A-0.606CRBPCorbus Pharmaceuticals4.3194 of 5 stars$9.37-1.4%$49.00+422.9%-80.9%$116.42MN/A-1.9740News CoverageAnalyst ForecastBMEABiomea Fusion3.3155 of 5 stars$1.96+1.6%$14.80+655.1%-74.7%$114.85MN/A-0.6550News CoveragePYXSPyxis Oncology2.355 of 5 stars$1.90+4.4%$7.75+307.9%-43.2%$112.87M$16.15M-1.1960Gap UpEQEquillium0.9274 of 5 stars$1.71-8.6%$1.00-41.5%+89.5%$111.27M$16.55M-3.0540Short Interest ↓FATEFate Therapeutics3.9732 of 5 stars$0.96-0.8%$3.30+245.3%-76.0%$111.07M$13.63M-0.66550Positive News Related Companies and Tools Related Companies Oncolytics Biotech Alternatives TuHURA Biosciences Alternatives Protara Therapeutics Alternatives Compugen Alternatives Inhibikase Therapeutics Alternatives Corbus Pharmaceuticals Alternatives Biomea Fusion Alternatives Pyxis Oncology Alternatives Equillium Alternatives Fate Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ITRM) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
